Genetic testing for inherited heart diseases: Longitudinal impact on health-related quality of life

Genetics in Medicine

Volumn 14, Issue 8, 2012, Pages 749-752

  Ingles, Jodie ^a,b   Yeates, Laura ^a   Obrien, Lisa ^c   McGaughran, Julie ^c,d   Scuffham, Paul A ^e   Atherton, John ^c,d   Semsarian, Christopher ^a,b,f  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

genetic testing; health related quality of life; hypertrophic cardiomyopathy; long QT syndrome

Indexed keywords

ADULT; ARTICLE; CARDIOMYOPATHY; FAMILIAL DILATED CARDIOMYOPATHY; FEMALE; FOLLOW UP; GENETIC SCREENING; HEALTH SURVEY; HEART DISEASE; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PREDICTION; PROSPECTIVE STUDY; QUALITY OF LIFE; SHORT FORM 36;

EID: 84864689397     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2012.47     Document Type: Article

References (26)

1. Ingles J, Yeates L, Hunt L, et al. Health status of cardiac genetic disease patients and their at-risk relatives. Int J Cardiol 2011; e-pub ahead of print 17 September 2011.
2. Ingles J, Yeates L, Semsarian C. The emerging role of the cardiac genetic counselor. Heart Rhythm 2011;8:1958-1962.
3. Ingles J, Semsarian C. Sudden cardiac death in the young: a clinical genetic approach. Intern Med J 2007;37:32-37.
4. Christiaans I, van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Genetic counseling and cardiac care in predictively tested hypertrophic cardiomyopathy mutation carriers: the patients' perspective. Am J Med Genet A 2009;149A:1444-1451.
5. Hershberger RE, Cowan J, Morales A, Siegfried JD. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail 2009;2:253-261.
6. Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 2005;42:e59.
7. Konstam V, Salem D, Pouleur H, et al. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol 1996;78:890-895.
8. Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 2000;8:731-738.
9. Prévost C, Veillette S, Perron M, et al. Psychosocial impact of predictive testing for myotonic dystrophy type 1. Am J Med Genet A 2004;126A:68-77.
10. Tibben A. Predictive testing for Huntington's disease. Brain Res Bull 2007;72:165-171.
11. Christiaans I, van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study. Am J Med Genet A 2009;149A:602-612.
12. Ingles J, Lind JM, Phongsavan P, Semsarian C. Psychosocial impact of specialized cardiac genetic clinics for hypertrophic cardiomyopathy. Genet Med 2008;10:117-120.
13. van Maarle MC, Stouthard ME, Bonsel GJ. Quality of life in a family based genetic cascade screening programme for familial hypercholesterolaemia: a longitudinal study among participants. J Med Genet 2003;40:e3.
14. Hendriks KS, Hendriks MM, Birnie E, et al. Familial disease with a risk of sudden death: a longitudinal study of the psychological consequences of predictive testing for long QT syndrome. Heart Rhythm 2008;5:719-724.
15. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001;10:405-13; discussion 415.
16. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.
17. McCallum J. The SF-36 in an Australian sample: validating a new, generic health status measure. Aust J Public Health 1995;19:160-166.
18. Ingles J, McGaughran J, Vohra J, et al. Establishment of an Australian National Genetic Heart Disease Registry. Heart Lung Circ 2008;17:463-467.
19. Hawthorne G, Osborne RH, Taylor A, Sansoni J. The SF36 Version 2: critical analyses of population weights, scoring algorithms and population norms. Qual Life Res 2007;16:661-673.
20. Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive (+)-phenotype negative (-) family members in hypertrophic cardiomyopathy. Am J Cardiol 2011;107:604-608.
21. Gray B, Ingles J, Semsarian C. Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy. Int J Cardiol 2011;152:258-259.
22. Stiggelbout AM, de Vogel-Voogt E. Health state utilities: a framework for studying the gap between the imagined and the real. Value Health 2008;11:76-87.
23. Schwartz CE, Bode R, Repucci N, Becker J, Sprangers MA, Fayers PM. The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual Life Res 2006;15:1533-1550.
24. Meulenkamp TM, Tibben A, Mollema ED, et al. Predictive genetic testing for cardiovascular diseases: impact on carrier children. Am J Med Genet A 2008;146A:3136-3146.
25. Smets EM, Stam MM, Meulenkamp TM, et al. Health-related quality of life of children with a positive carrier status for inherited cardiovascular diseases. Am J Med Genet A 2008;146A:700-707.
26. Biesecker BB. Goals of genetic counseling. Clin Genet 2001;60:323-330.